News

GMO acreage reaches new high
Enlarge image

BusinessEUSpainGermanyPoland

GMO acreage reaches new high

21.02.2013 - Global acreage of biotech crops have increased by 6% last year. Europe contributes only 0.075%.

Brussels/Manila - Genetically modified (GM) soybeans, maize, cotton and rapeseed were planted on 170.3 million hectares last year, according to figures from the International Service for the Acquisition of Agri-Biotech Applications (ISAAA). However, the adoption of biotech crops has become slower. After double digit growth rates three years ago, this year the cultivation area increased only by 6 percent or 10.3 million hectares compared to 2011. 

However, Europe remains a minor player in the growing market for GMOs due to public hostility to GMOs. The EU countries grew 129,071 hectares of Bt maize, about 14,000 hectares more than in 2011. Spain remained the leading EU country for GMO acreage with 116,306 hectares in 2012. Poland discontinued the planting of biotech maize.  The US (69.5m ha, +0.7%), Brazil (36.6m ha, +20,8%), Argentina (23.9m ha, +0,8%), Canada (11.6m ha, +11,5), and India (10.6m ha, +1,8%) were the leading GMO producers. Global Adoption of GM soybeans (+8%), cotton (+7%), maize (+4%), and rapeseed (+5%) increased as compared to 2011.  

"There is one principal and overwhelming reason that underpins the trust and confidence of farmers in biotechnology: biotech crops deliver substantial, and sustainable, socio-economic and environmental benefits," stressed ISAAA chief Clive James. In fact, German BASF and Monsanto both filed for US approval of the first drought-tolerant crop last year. However, the US Department of Agriculture recently delayed the approval of new herbicide-tolerant GMOs because weeds are becoming more and more resistant to the herbicide Glyphosate, which is marketed together with Glyphosate-tolerant GMOs since 1996.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/gmo-acreage-reaches-new-high.html

CommercialisationEU

10.02.2016 In future, meds will come in packages sporting a unique barcode and an anti-tampering device. These measures are part of the EU’s new regulation to safeguard against falsified medicines.

Clinical ResearchFrancePortugalEU

05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. A preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.

M&ASwitzerland

04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.

FinancingEUUKBelgium

01.02.2016 Newly formed Medicxi Ventures, a life sciences-dedicated VC firm based in London, Geneva and Jersey, has closed a €210m investment fund to reinvest in European early-stage assets.

ResearchUKEU

01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.

M&ASwedenIceland

28.01.2016 Swedish infectious disease specialist Enzymatica has bagged Icelandic company Zymetech, who produces the patent-protected enzyme used in Enzymatica’s own common cold blocker ColdZyme.

R&DUK

27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.

Clinical TrialsGermany

25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.

AMREU

21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.

M&AFinland

19.01.2016 Biotie Therapies has long been expanding its business in the US. Now, the Finnish company is set to be taken over by US company Acorda Therapeutics, which is paying €321m for the shares.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS (CH)0.05 CHF25.00%
  • ZEALAND PHARMA (DK)105.50 DKK14.05%
  • SARTORIUS (D)244.45 EUR12.88%

FLOP

  • PAION (D)1.25 EUR-36.55%
  • SWEDISH ORPHAN BIOVITRUM (S)12.45 USD-23.38%
  • BIOTIE THERAPEUTICS (FI)0.14 EUR-22.22%

TOP

  • VERONA PHARMA (UK)3.30 GBP24.5%
  • IXICO (UK)35.75 GBP21.2%
  • SAREUM HOLDINGS (UK)0.30 GBP15.4%

FLOP

  • BIONOR PHARMA (N)0.81 NOK-52.9%
  • PAION (D)1.25 EUR-48.6%
  • CYTOS (CH)0.25 CHF-34.2%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)24.50 SEK3081.8%
  • NICOX (F)6.80 EUR245.2%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)8.65 SEK-85.8%
  • BIOTEST (D)13.40 EUR-85.5%
  • EVOCUTIS (UK)0.08 GBP-71.4%

No liability assumed, Date: 10.02.2016